Structural Alerts for Toxicity

  title={Structural Alerts for Toxicity},
  author={Julian Blagg},
  journal={Medicinal Chemistry for Practitioners},
  • J. Blagg
  • Published 15 September 2010
  • Biology
  • Medicinal Chemistry for Practitioners
This chapter summarizes structural alerts where there is a significant weight of evidence that their incorporation into a drug candidate molecule is likely to result in a higher than average incidence of attrition due to adverse safety/or toxicity findings. The mechanism of formation of reactive metabolites from each structural alert is summarized. The structure–toxicity relationships and the boundary of definition for each structural alert are discussed. The benefits of low exposure and… 
Computational Toxicology Methods in Chemical Library Design and High-Throughput Screening Hit Validation.
This chapter focuses on the application of computational molecular filters, applied either prescreening or postscreening, to identify and remove known reactive and/or potentially toxic compounds from consideration in drug discovery campaigns.
Evidence for the in vitro bioactivation of aminopyrazole derivatives: trapping reactive aminopyrazole intermediates using glutathione ethyl ester in human liver microsomes.
Evidence is presented for the bioactivation of a series of aminopyrazole derivatives via LC-MS detection of glutathione ethyl ester-trapped reactive intermediates formed in human liver microsomal incubations that indicate that the aminogyrazole motif, within specific contexts, may be considered a new structural alert for the potential formation of reactive metabolites.
Computational Toxicology and Drug Discovery.
This chapter provides an overview of the field and describes the application of computational toxicology throughout the entire discovery and development process.
The Need for, and the Role of the Toxicological Chemist in the Design of Safer Chemicals
  • S. Devito
  • Chemistry
    Toxicological sciences : an official journal of the Society of Toxicology
  • 2018
The role of the toxicological chemist is illustrated, an individual who is formally trained in synthetic organic chemistry, biochemistry, physiology, toxicology, environmental science, and in the relationships between structure and commercial use efficacy, structure and toxicity,ructure and environmental fate and effects, and global hazard, and trained to integrate this knowledge to design safer commercially efficacious chemicals.
STopTox: An in Silico Alternative to Animal Testing for Acute Systemic and Topical Toxicity
STopTox, a comprehensive collection of computational models that can be used as an alternative to in vivo 6-pack tests for predicting the toxicity hazard of small organic molecules, is developed.
Virtual Screening Directly Identifies New Fragment-Sized Inhibitors of Carboxylesterase Notum with Nanomolar Activity.
The [1,2,4]triazolo[4,3-b]pyradizin-3(2H)-one series 4 represent a new chemical class of Notum inhibitors and the first to be discovered by a VS campaign, demonstrating the value of VS with well-designed docking models based on X-ray structures.
Dear Editor, thank you for reviewing our manuscript “Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign” submitted for publication in European Journal of Medicinal Chemistry
The results indicate that PTR1 has a preference to bind inhibitors, which resemble its biopterin/folic acid substrates, such as the 2,4-diaminopyrimidine derivatives.
Locally weighted learning methods for predicting dose-dependent toxicity with application to the human maximum recommended daily dose.
This article demonstrates, via application to the human maximum recommended daily dose data, that locally weighted learning methods, such as k-nearest neighbors, are well suited for predicting toxicological effects of structurally diverse compounds.


Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
While RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, the analysis suggests a need for a more integrated screening paradigm for chemical hazard identification in drug discovery.
Structural Alerts, Reactive Metabolites, and Protein Covalent Binding: How Reliable Are These Attributes as Predictors of Drug Toxicity?
Current approaches to evaluate bioactivation potential of new compounds with particular emphasis on the advantages and limitation of these assays are outlined.
A comprehensive listing of bioactivation pathways of organic functional groups.
This review aims to serve as a resource describing the structural diversity of functional groups or structural motifs commonly utilized in drug design efforts as well as experimental approaches that could be taken to evaluate whether a "structural alert" in a new drug candidate undergoes bioactivation to reactive metabolites.
Minimising the potential for metabolic activation in drug discovery
Major themes explored in this review include a comprehensive cataloguing of bioactivation pathways of functional groups commonly utilised in drug design efforts with appropriate strategies towards detection of corresponding reactive intermediates.
Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?
The basic methodology that is currently utilized to evaluate the bioactivation potential of new compounds is reviewed, with particular emphasis on the advantages and limitation of these assays.
Identification of the structural requirements for mutagencitiy, by incorporating molecular flexibility and metabolic activation of chemicals. II. General Ames mutagenicity model.
The focus of the present work was to build a general Mutagenicity model predicting mutagenicity with respect to any of the Ames tester strains, found to have 82% sensitivity, 89% specificity, and 88% concordance for training set chemicals.
Screening of drug candidates for their drug--drug interaction potential.
Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.
This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Laboratories.
Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
A comprehensive analysis of the biochemical basis and known structure-activity relationships for P 450 inactivation by xenobiotics is described and the current state-of-the-art of the methodology used in predicting the magnitude of DDIs using in vitro P450 inactivation data and human pharmacokinetic parameters is discussed in detail.